Building on clinical data from several single - agent immunotherapy clinical trials, and by engaging scientists with unique and complementary expertise from eight institutions and three industry partners, the BEAT - HIV Collaboratory's central mission will be to develop and test innovative
combined immunotherapy strategies to eradicate and / or permanently suppress HIV replication in the absence of ART.
Not exact matches
Combining their
strategy with an existing
immunotherapy treatment that works by releasing the «brakes» on immune cells, they found they could shrink melanoma tumors, and prolong survival in preclinical models for melanoma.
Therefore, «this finding may represent a future therapeutic strategic to
combine with other
strategies, such as
immunotherapy, chemotherapy or inhibitors against specific signalling routes of the tumour cells.»
Moreover, the efficiency of
immunotherapy was further increased by
combining this adoptive transfer with the current clinical
strategy of reactivating the T cell antitumor response with antibodies to the receptor PD - 1.